Brain metastasis is common in patients with non-small cell lung cancer (NSCLC) and it is associatedwith poorer prognosis. Several options to control the secondary brain tumors in the context includechemotherapy, whole-brain radiation, stereotactic surgery, surgery. However, chemotherapy is ineffectiveto those patients because of poor penetration through the blood-brain barrier. Whole-brain radiation therapyused to be a standard option for brain metastases. However, it potentially damages normal brain tissuesand causes neurocognitive decline. Stereotactic radiotherapy has been considered in cases of three orfewer lesions, and the lesions less than 3 cm. In selective cases, surgical removal of brain metastases canbe done. These local therapies were accompanied by systemic treatment due to spreading of the cancer.Recently, molecular targeted therapy has opened up a new era in cancer treatment, especially NSCLC withbrain metastases. In this review, we discuss brain metastases occurring in NSCLC patients with driver gene mutations with some briefly demonstrated cases.